Member Info for thedean5

Https://youtu.be/6giJsvGFNow?t=23

While hVIVO (HVO) does not have a formal rule stating they will only announce deals in the millions, their recent Regulatory News Service (RNS) activity shows a clear focus on multi-million pound contracts that are considered "material" to their growth strategy.Recent Major RNS Announcements£6 Million Influenza Deal: Today, May 7, 2026, the company announced a £6 million contract to test a monoclonal antibody treatment for influenza.£5 Million+ CRS Contracts: In November 2025, hVIVO reported over £5 million in new contracts through its German subsidiary, CRS.Pivotal Phase III Deal: They previously secured a landmark multi-year contract for a Phase III human challenge trial with ILiAD Biotechnologies, which analysts expect to significantly impact

Https://www.youtube.com/live/Py9m1oia72k?si=JrUFZcCPkhjUc9Sy 21 minutes in

Https://www.youtube.com/watch?v=2-NACmNhiY0&t=81s

Https://www.youtube.com/watch?v=JLrN2PtrVU8&t=6s

Https://www.youtube.com/watch?v=kKvqsYTlsSo&t=1s

Alongside the RSV‑B model, hVIVO has developed a new human metapneumovirus (hMPV) challenge model. hMPV is a close relative of RSV and is increasingly recognised as a significant respiratory pathogen. As developers move toward combination respiratory vaccines, validated challenge models for each component become essential. The hMPV model has shown strong infection rates and robust symptoms, making it a valuable addition to the respiratory challenge platform. Development of a PIV model has now also begun.

Together, the RSV‑A, RSV‑B, and hMPV models provide a comprehensive suite of tools for evaluating next‑generation vaccines and therapeutics. They enable precise, early‑phase assessment of each component in a controlled environment, reducing uncertainty and accelerating development.

Looking Ahead

The future of respiratory virus research will rely increasingly on tools that can generate high‑quality data early in development. Human challenge trials are uniquely positioned to meet this need. They offer a controlled setting for understanding infection dynamics, identifying correlates of protection, and evaluating the performance of vaccines and antivirals long before large field trials are possible.

Https://www.cnbc.com/2026/02/18/fda-chief-warns-us-is-losing-ground-to-china-in-early-drug-trials.html

Https://theconversation.com/whooping-cough-cases-are-at-their-highest-level-in-35-years-so-why-the-surge-275082

Any mention of a tr1 after rathbone and octopus after selling millions of shares and are they still paying the pitiful dividend

Https://www.youtube.com/watch?v=08A3lnn8iF8&t=73s

Https://pharmaphorum.com/rd/unlocking-future-obesity-treatment

Https://www.news-medical.net/whitepaper/20260109/Ensuring-success-in-outpatient-vaccine-trials.aspx

Https://www.proactiveinvestors.co.uk/companies/news/1084331/broker-backs-hvivo-2026-rebound-1084331.html

Https://www.openaccessgovernment.org/new-nasal-vaccine-could-stop-whooping-cough-spreading-trial-finds/202294/

Https://www.youtube.com/watch?v=2Eu4esGxAco&t=15s

Https://www.youtube.com/watch?v=TeSyS-xq9w0&t=16s

Https://www.youtube.com/watch?v=0AjTElIYbVU

Https://commission.europa.eu/news-and-media/news/making-europe-global-leader-life-sciences-2025-07-02_en

Https://youtu.be/watbaEMO7YM?si=HHvV-v9NvPKiumjq